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Abstract 
Background & Purpose 
Antiarrhythmic β-blockers are used in patients at risk of myocardial ischaemia, but the 
survival benefit and mechanisms are unclear. We hypothesised that β-blockers do not prevent 
ventricular fibrillation (VF), but instead inhibit the ability of catecholamines to facilitate 
ischaemia-induced VF, limiting the scope of their usefulness. 
Experimental Approach 
ECGs were analysed from ischaemic Langendorff-perfused rat hearts perfused with 
adrenoceptor antagonists and/or exogenous catecholamines (313 nM noradrenaline+75 nM 
adrenaline; CATs) in a blinded and randomised study. Ischaemic zone (IZ) size was 
deliberately made small or large. 
Key Results 
In rat hearts with large IZs, ischaemia-induced VF incidence was high in controls. Atenolol, 
butoxamine and trimazosin had no effect on VF at concentrations with β1, β2 or α1 
adrenoceptor specificity and selectivity, respectively (shown in separate rat aortae myography 
experiments). In hearts with small IZs and a low baseline incidence of ischaemia-induced VF, 
CATs, delivered to the uninvolved zone (UZ), increased ischaemia-induced VF incidence. 
This effect was not mimicked by atrial pacing, and hence not due to sinus tachycardia. 
However, the CATs-facilitated increase in ischaemia-induced VF was inhibited by atenolol 
and butoxamine (but not trimazosin), indicative of β1 and β2 but not α1 adrenoceptor 
involvement (confirmed by immunoblot analysis of downstream phosphoproteins). 
Furthermore, CATs did not facilitate VF in low-flow globally ischaemic hearts, which have 
no UZ. 
Conclusions and Implications 
Catecholamines facilitated ischaemia-induced VF when risk was low, acting via β1 and β2 
adrenoceptors located in the UZ. There was no scope for facilitation when VF risk was high 
(large IZ), which may explain why β-blockers have equivocal effectiveness in humans. 
 
Keywords: 
Adrenaline; adrenergic; arrhythmia; myocardial ischaemia; noradrenaline; ventricular 
fibrillation 
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Abbreviations 
ACh, acetylcholine; AD, adrenaline; AP, action potential; AR, adrenoceptor; BG, bigeminy; 
CATs, catecholamine mixture (313 nM NA + 75 nM AD); CRC, concentration response 
curve; cTnI, cardiac troponin I; CVD, cardiovascular disease; ECG, electrocardiogram; HR, 
heart rate; IZ, ischaemic zone; MI, myocardial infarction; NA, noradrenaline; NO, nitric 
oxide; NOEL, no effect level; PE, phenylephrine; RyR2, ryanodine receptor type 2; SCD, 
sudden cardiac death; SNS, sympathetic nervous system; TVW, total ventricular weight; UZ, 
uninvolved zone; VF, ventricular fibrillation; VPB, ventricular premature beat; VT, 
ventricular tachycardia. 
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Introduction 
Sudden cardiac death (SCD) contributes >60% of cardiovascular disease (CVD)-related 
deaths, with a majority of these due to ventricular fibrillation (VF) caused by acute 
myocardial ischaemia, and the search for targetable mechanisms has proven challenging 
(Adabag et al., 2010; John et al., 2012). 
During the first 30 min of ischaemia (the ‘phase 1’ period), VF risk is intrinsically 
proportional to the severity of ischaemia, which is determined primarily by ischaemic zone 
(IZ) size, set by occlusion location, and by collateral flow (Curtis, 1998; Ridley et al., 1992). 
Separately, VF risk can be modulated by extrinsic factors such as heart rate (HR) and blood-
born factors (Curtis et al., 1993). The relationships between VF incidence and IZ size, and 
other independent variables, are well-characterized in the rat Langendorff preparation, 
rendering it a tractable assay system (Curtis, 1998).  
Catecholamines have long been regarded as mediators of ischaemia-induced VF with 
myocardial β1 agonism the most plausible mechanism; however there are inconsistencies in 
the published literature with regard to the relationship between the absolute levels of 
catecholamines accumulating in the ischaemic territory and the incidence of ischaemia-
induced ventricular arrhythmias (see discussion for further analysis) (Curtis et al., 1993). 
Thus, in animals, ischaemia causes catecholamine accumulation in the IZ (Lameris et al., 
2000; Schömig et al., 1984) yet the timing does not accord with the timing of VF onset 
(Curtis, 1998). Adrenoceptor (AR) antagonists inhibit ischaemia-induced VF, yet 
doses/concentrations tested often lack selectivity for their intended target AR, and effects 
(e.g. a reduction in ischaemia-induced VF incidence) are better explained by non-specific and 
even extra-cardiac, off-target effects, as suggested by others (Daugherty et al., 1986; Tölg et 
al., 1997). Some effects are model-dependent, e.g. off-target β2 antagonist actions in acutely 
prepared animals (e.g. rat) elevates circulating blood potassium concentrations resulting in 
VF suppression, an artefact that does not occur in conscious animals subjected to regional 
ischaemia when fully recovered from preparative surgery (Botting et al., 1983; Paletta et al., 
1989) or indeed in isolated hearts where, due to delivery of Krebs directly to the coronary 
vasculature and an absence of a circulation, the scope for an alteration in circulating blood 
potassium is zero. In patients with previous ventricular tachycardia (VT) or VF, and acute 
myocardial infarction (MI), plasma catecholamines can become elevated (Meredith et al., 
1991; Slavikova et al., 2007). β AR antagonists reduce mortality in such patients, but only 
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moderately (Nademanee et al., 2000; β-Blocker Heart Attack Study Group, 1981), and their 
specific effects on VF remain unclear, despite decades of use (ISIS-1 Collaborative Group, 
1988; The MIAMI Trial Research Group, 1985). 
It is important to clarify whether catecholamines are important therapeutic targets for VF 
suppression or not. It may be possible to reconcile published data if it were the case that 
catecholamines facilitate phase 1 ischaemia-induced VF rather than mediate it. The corollary 
of this novel hypothesis is that the relevance of catecholamines will depend on the influence 
of other factors such as IZ size. Here we found that catecholamines acting primarily in the 
non-ischaemic uninvolved zone (UZ) facilitated ischaemia-induced VF in rat isolated hearts, 
but only when IZ was small (rendering VF risk low). The mechanism, identified using 
selective and specific AR antagonists and confirmatory immunoblotting, required dual 
agonism of β1 and β2 ARs. These data explain the likely role of catecholamines in SCD/VF 
and receptor mechanism, and the limits of achievable protection from AR antagonists. 
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Methods 
Ethical statement 
Experiments were approved by the King’s College London ethics review board and 
performed in accordance with the guidelines from Directive 2010/63/EU of the European 
Parliament on the protection of animals used for scientific purposes, ARRIVE (Kilkenny et 
al., 2010), the United Kingdom Home office Guide on the Operation of the Animals 
(Scientific Procedures) Act 1986, and recent guidelines on experimental design and analysis 
(Curtis et al., 2015). Animal housing and husbandry were exactly as described previously 
(Andrag & Curtis, 2013), and all test solutions and data analysis were blinded by way of 
coding. To blind the study, the operator gave a second person a book that listed the groups to 
be studied. The second person wrote a code by the name of each group (e.g. Brighton, Palace, 
ManU) and relabelled the stock bottles (identical) with the name of the experimental group. 
The operator then aliquoted the coded stocks, and the code book was kept by the second 
person until the experiment was completed and analysed. A total of 620 animals were 
randomised to groups. 
 
Animals, general experimental methods and experimental strategy 
Male Wistar rats (Harlan UK; 220-410g) were anaesthetised by intraperitoneal injection of a 
lethal dose of sodium pentobarbitone (170 mg kg
-1
) and co-administered sodium heparin (160 
IU kg
-1
) (Wilder et al., 2016). A surgical level of anaesthesia was determined by the absence 
of pedal and corneal reflexes, prior to cardiac excision and exsanguination. Hearts were 
immediately removed and arrested in ice-cold modified Krebs control solution (hereafter 
called ‘Krebs’), containing NaCl 118.5 mM, CaCl2 1.4 mM, glucose 11.1 mM, NaHCO3 
25.0 mM, MgSO4 1.2 mM, NaH2PO4 1.2 mM and KCl 3 mM, then mounted on to a metal 
cannula via the aorta for Langendorff perfusion with gassed and warmed (95% O2: 5% CO2; 
pH 7.4; 37°C) Krebs. All perfusion solutions were filtered (5 µm pore size) before use and 
delivered at a constant pressure of approximately 80 mmHg (generated by the height of the 
perfusion columns). A unipolar electrocardiogram (ECG) recording was used for assessment 
of cardiac rhythm by inserting a wire electrode into the left ventricular wall at the apex of the 
heart, as described previously (Dhanjal et al., 2013), and ventricular arrhythmias (figure 1) 
were identified using the Lambeth Conventions II definitions (Curtis et al., 2013). 
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To obtain coronary occlusion, a silk suture sewn under the left main coronary artery was 
threaded through a polythene tube, which was tightened and clamped using curved Spencer 
Wells forceps to induce regional ischaemia, and later loosened to achieve reperfusion 
(normally 30 min after the onset of ischaemia). To generate an IZ of specific size, a silk 
suture was placed loosely around the left main coronary artery at one of three predetermined 
set levels: distal, medial or proximal to the atrial appendage, generating a small, medium or 
large IZ, respectively (table 1) (Andrag & Curtis, 2013; Ridley et al., 1992).  
After reperfusion, the IZ was identified by perfusing hearts with disulphine blue dye (Patent 
blue VF sodium salt, Sigma Aldrich®, UK), followed by re-occlusion of the left main 
coronary artery. Hearts were then perfused with dye-free test solution in order to wash out 
any excess blue dye from the UZ. The IZ and UZ were dissected and weighed, and the IZ was 
quantified as a percentage of total ventricular weight (TVW). In hearts in which reperfusion 
was not possible because IZs and UZs were required for immunoblotting (catecholamines + 
antagonist study), the IZ was judged from the location of the occluder and downstream tissue 
discolouration, and dissected by eye, with values verified by % reduction in coronary flow 
following coronary ligation (Curtis, 1998).  
The need to generate groups of different IZ sizes is an intrinsic aspect of our experimental 
strategy and is predicated by the hypothesis that catecholamines facilitate ischaemia-induced 
VF, and this is feasible only when VF risk is low, meaning that there exists scope for the 
incidence of VF in a group of hearts to be increased. When IZ is large (table 1) it is well 
established that in a group of rat isolated hearts, the incidence of ischaemia-induced VF will 
be high, meaning the scope for facilitation of VF will be too low for facilitation to be 
pathophysiologically relevant, or indeed detectable by statistical analysis in a typical study of 
no more than n=20 hearts/group (Curtis, 1998). In addition to statistical considerations, 
evaluating possible facilitation of VF in hearts with smaller IZ sizes makes biological sense 
since it is known that numerous factors appear to play a role in arrhythmogenesis but that 
their relevance becomes less as VF risk becomes greater owing to ‘optimization’ of 
arrhythmogenic conditions, e.g., as a consequence of the IZ size being large (Curtis, 1998; 
Curtis et al., 1993). Arrhythmogenesis is complex and there is mediator redundancy, known 
as ‘pathophysiological reserve’ whereby numerous factors may be sufficient for 
arrhythmogenesis; this means that each individual factors will not be necessary for 
arrhythmogenesis under all conditions (Curtis, 1998; Curtis et al., 1993). This is nuanced, but 
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the nuance is important, and addressing it distinguishes our objectives from the more 
simplistic and fallacious concept of catecholamines ‘causing’ ischaemia-induced VF. 
 
Experimental protocols 
Throughout each experimental protocol, a range of ancillary variables including HR, 
coronary flow, PR and QT interval at 90% repolarization (QT90), were recorded every 5 
minutes, and the occurrence of ventricular arrhythmias was noted in each 5 minute time 
interval. The QT90 is recorded in rat studies because the T wave is not distinct and the QRST 
is a single complex that returns to isoelectric asymptotically, rendering the conventional QT 
interval (at 100% repolarization) very difficult to measure accurately; use of QT90 is validated 
and long established  (Rees & Curtis, 1993; Ridley & Curtis, 1992). An arrhythmia score was 
assigned to each heart for ischaemia and (separately) for reperfusion in order to permit 
parametric statistical analysis. All these assessments were as described previously (Wilder et 
al., 2016). 
Hearts were perfused initially with Krebs for 5 minutes and excluded if predetermined  
criteria were not met (Wilder et al., 2016). In total, 38 hearts were excluded and these were 
immediately replaced to maintain group sizes while maintaining the randomization (see 
below). Baseline recordings were then made, followed by switch to test solution that varied 
according to study subset. In the initial study to examine the effects of catecholamines on VF 
in hearts with different predetermined IZ sizes, these were vehicle (Krebs + 50 µM ascorbate) 
or catecholamine mixture (CATs: 313 nM noradrenaline [NA] and 75 nM adrenaline [AD] + 
50 µM ascorbate). In subsequent studies to identify adrenoceptor antagonists with no non-
specific off target pharmacology (in hearts perfused without CATs) these were vehicle 
(Krebs), 1 or 10 µM atenolol, butoxamine, prazosin, terazosin or trimazosin. In studies to 
identify the receptor mechanisms involved in mediating CAT effects on VF, these were 
vehicle (Krebs + 50 µM ascorbate), CATs or CATs + 1 µM atenolol, butoxamine or 
trimazosin. The experimental details for these groups are shown in (figure 2). The CATs 
mixture used restores HR in Langendorff perfused hearts to rates seen in conscious rats 
(Curtis et al., 1985), and the concentration ratio of NA to AD is representative of the ratio 
encountered in human plasma (Baumgartner et al., 1985; Goldstein et al., 2003), especially 
under conditions of stress (Coplan et al., 1989; Ratge et al., 1986). We have explained the 
basis for the CATs mixture more fully, and characterised and validated its use in a previous 
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study focused on the role of CATs in mediating VF during infarct evolution (which occurs 
after periods of ischaemia of more sustained duration than necessary to evoke so-called phase 
1 arrhythmias, which are the focus of the present study) (Clements-Jewery et al., 2009). 
Ten minutes after solution switch/initiation of pacing, the coronary ligature was tightened to 
induce regional ischaemia, which was maintained for 30 minutes and terminated by 
reperfusion. Although not the main focus of the present study, this allowed examination of 
CAT effects (in hearts perfused with CATs) on reperfusion-induced VF, with further 
monitoring of ancillary variables for 10 minutes (figure 2). Of each group in the pacing study, 
50% of hearts were reperfused to enable future sub-analysis of cardiac biochemistry between 
time-matched reperfused and ischaemic tissue, using snap frozen samples (-80°C). Hearts in 
the catecholamines + antagonist study were not reperfused because IZs and UZs (dissected 
and frozen in liquid nitrogen) were required for later immunoblot analysis. 
 
Supraventricular pacing 
In order to establish or rule out whether CATs facilitate ischaemia-induced VF via effects on 
HR, a separate group of Krebs’ perfused hearts (figure 1) was paced via the right atrium at a 
rate to match that of the average pre-ischaemia rate caused by CAT perfusion (found to be 
405 beats min
-1
) using a silver wire bipolar electrode, connected to a stimulator (CD-S103, 
Cudos, UK). The stimulator was linked to a PowerLab™ system (PowerLab 4/35 and Animal 
Bio Amp, ADInstruments, UK; sampling rate 1 kHz), and hearts were stimulated with square 
wave pulses at double the threshold pulse width (0.34 ± 0.05 ms duration), and double the 
threshold voltage (1.75 ± 0.2 V) at 6.75 Hz. Regional ischaemia was induced as described 
above, to generate small IZs, allowing scope for examining whether sinus tachycardia 
matching that evoked by CATs was sufficient to increase the incidence of ischaemia-induced 
VF. 
 
Low flow global ischaemia 
With regional ischaemia in the rat isolated heart, there is limited scope for delivery of 
exogenous CATs to the IZ owing to the uniform low level of coronary collaterals that 
delivers a flow to the IZ that is no more than 5% of flow in the UZ (Curtis, 1998). This means 
that the aforementioned regional ischaemia studies allow testing only of whether CATs acting 
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in the perfused UZ facilitate ischaemia-induced VF. Therefore, to test the possibility that, 
with a more substantial level of collateral flow, CATs may additionally act in the IZ to 
facilitate ischaemia-induced VF, required a different model. We therefore elaborated a low 
flow global ischaemia model in which the IZ is continuously perfused to allow CAT delivery. 
Importantly, any facilitation of ischaemia-induced VF by CATs in a low flow global 
ischaemia model can occur only by actions mediated in the IZ (there is no UZ). 
Hearts were dissected and cannulated, and an ECG lead positioned as described above. 
Following 15 minutes of baseline perfusion with Krebs, the perfusate was switched to test 
solution and coronary flow was reduced to one of three set levels for 60 minutes: severe (0.8 
ml min
-1
), moderate (2 ml min
-1
), or mild (4 ml min
-1
) low flow global ischaemia using fixed 
resistance (clamps) to regulate inflow to the cannula (figure 2). A group of time-matched 
regionally ischaemic hearts with large IZs was included in the study to act as a positive 
control for comparative purposes (figure 2). Hearts were perfused with vehicle (Krebs + 50 
µM ascorbate) or CATs. HR, coronary flow, RR and QT90 interval, ventricular arrhythmias, 
and heart temperature were recorded at 5 minute intervals throughout the protocol. The 
duration of ischaemia was extended beyond the 30 min sufficient to allow evaluation of phase 
1 arrhythmias in the regionally ischaemic heart in order to provide a characterization of the 
arrhythmia profile, since this rat Langendorff low flow global ischaemia model is new and 
uncharacterized. Thus the experiment was terminated after 60 min of ischaemia. 
 
AR antagonist specificity and selectivity and use of tissue bath myography 
Selection of AR antagonist concentrations was guided by published IC50 values, but in order 
to be sure that the chosen agents possessed specificity (effects attributable to an action on the 
intended AR), and selectivity (effects attributable only to an action on the intended AR), a 
dual approach was taken. Specificity was identified in two ways: (i) from AR effects on well-
established CAT responses in perfused hearts (for example, inhibition of CAT-induced sinus 
tachycardia denoting β1 antagonism) and (ii) from separate blood vessel bioassay studies. For 
the latter, concentration response curves (CRCs) were constructed using isolated rat thoracic 
aortae and tissue bath myography (Myobath II 4-channel tissue bath, WPI, UK). Thoracic 
aortae were dissected from anaesthetised male Wistar rats (Harlan UK; 350-400g), and 
immediately immersed in cold Krebs-Ringer solution, containing: NaCl 118 mM, CaCl22H2O 
2.5 mM, glucose D (+) 11.1 mM, NaHCO3 25mM, MgSO4 1.2 mM, KH2PO4 1.2 mM, and 
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KCl 4.8 mM, cleared of perivascular connective and adipose tissue, and cut into 4 x 3 mm 
length rings using 5 scalpel blades mounted together (equidistance apart). Aortic rings were 
denuded (endothelium removed) for α1 AR antagonist experiments in order to preclude β AR 
agonism-induced NO-mediated vasodilation (Brawley et al., 2000). An adapted 21 gauge 
needle was inserted into the vessel rings and rolled gently against the dissecting dish 10 to 15 
times in order to remove endothelia. 
Aortic rings were mounted and secured via a pair of intraluminal steel wires, and submerged 
in 15 ml tissue baths containing gassed and warmed (95% O2: 5% CO2; pH 7.4; 37°C) Krebs-
Ringer solution. CRCs were recorded using LabChart v7 software (ADInstruments, UK) and 
a PowerLab™ system (PowerLab 4/25 and Pod Expander, ADInstruments, UK; sampling 
rate 100 Hz).  
After a warm-up period of 60 minutes, during which time baseline vascular tension was set, 
vascular function was tested (achievement of a vasoconstriction to 60 mM KCl within 2 SDs 
from the study mean). Endothelium integrity was then assessed by pre-constricting with 1 
µM phenylephrine (PE), with a reversal of >70% of the PE-induced tone by 10 µM ACh 
taken to indicate the presence of intact endothelium (β AR constriction experiments), and a 
reduction of <20% taken to indicate the absence of endothelium (denuded vessels; α AR 
relaxation experiments). Each bath was subsequently washed out 3 times with Krebs-Ringer 
solution, and left for 15 minutes for tension to return to baseline. Vehicle (water), 1 or 10 µM 
AR antagonist (atenolol, butoxamine or trimazosin, volume-matched to vehicle) was added to 
each tissue bath and left to incubate for 30 minutes. In β AR CRC experiments, aortic rings 
were pre-constricted with 1 µM PE, and the response left to plateau (approximately 15 
minutes). The PE equilibrium constriction was defined as the tension immediately before the 
start of the agonist CRC, and was normalised to zero. Subsequently, cumulative β AR agonist 
CRCs were constructed by sequentially increasing the agonist concentration by 0.5 log units 
(dobutamine [β1 AR] or salbutamol [β2 AR]; 30 nM to 1 mM) in each tissue bath. Vessels 
were exposed to each concentration of agonist for 6 minutes before the next addition. In α AR 
CRC experiments in which aortic rings were not pre-constricted, α AR agonist CRCs were 
constructed by sequentially increasing the concentration of PE by 0.5 log units (30 nM to 1 
mM). Vessels were exposed to each concentration of PE for 2 minutes (30 nM to 100 µM) or 
5 minutes (300 µM and 1 mM) before the next addition. 
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Selectivity was established by a two-step process that tested an AR concentration that 
possessed specificity for a lack of non-selectivity. Here, non-selectivity is defined as the 
ability to inhibit ischaemia-induced VF in the absence of exogenous CATS. The complete 
strategy is as follows. When a concentration was shown to obtain expected evidence of 
specificity based on the drug’s conventional description (i.e., a β1 antagonist causing 
inhibition of CAT-induced sinus tachycardia, or an α1 antagonist causing inhibition of CAT-
induced vascular constriction in myograph studies) we tested this concentration to determine 
that it had no effect on ischaemia-induced VF in rat hearts perfused without exogenous 
CATs. To achieve the latter, rat hearts were subjected to coronary ligation by the method 
described above but with all ligatures located proximally to evoke a large IZ. Any AR 
antagonist shown to reduce ischaemia-induced VF incidence at the chosen concentration was 
deemed to lack selectivity at that concentration, since ischaemia-induced VF in hearts 
perfused without added CATs is CAT-unrelated by definition, and any suppression of such 
VF cannot be attributed to adrenoceptor antagonism. Several concentrations of AR antagonist 
were tested in separate hearts to determine the threshold concentration for any such loss of 
selectivity, defined from the No Effect Levels (NOELs) on VF incidence. 
Only AR antagonists at concentrations showing sufficient evidence of specificity and 
selectivity were chosen for subsequent studies to test for inhibition of facilitation of 
ischaemia-induced VF by CATs in hearts with smaller IZs, using the technique and methods 
outlined above.  
 
Immunoblotting 
To provide further evidence that the ARs chosen for study possessed the necessary specificity 
and selectivity, we probed for downstream signal indicative of AR agonism. For reasons 
explained in Results it was necessary to probe only for β1 and β2 signal. Frozen UZs and IZs 
from the catecholamines + antagonist study (n = 5/group, hearts chosen at random) were 
ground to a fine powder and homogenised in EDTA-free lysis buffer. Protein concentration in 
lysates was determined by performing the Bradford protein assay (Bradford, 1976). 
Following the addition of sample buffer (Ehler et al., 1999), samples were heat-denatured at 
95°C for 5 minutes, and subjected to SDS-PAGE (10% acrylamide for cTnI, or 6% 
acrylamide for RyR2). Proteins were subsequently transferred to PVDF membranes by 
electrophoretic transfer using a semi-dry (cTnI) or wet transfer (RyR2) method. For 
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immunoblot analysis of proteins, membranes were blocked in 10% (w/v) non-fat skimmed 
milk (Marvel, Premier Foods, UK) in TBST for 1 hour at room temperature, except for 
membranes containing RyR2, which were blocked in 5% (w/v) BSA in TBST for 1 hour. 
Membranes were incubated with primary antibodies overnight at 4°C, and were subsequently 
incubated with secondary antibodies for 2 hours at room temperature. Protein bands were 
detected with ECL Western Blotting Detection Reagents (GE Healthcare, UK). Films were 
developed in a Fuji X-ray film processor (RGII, Fuji), and protein band density determined 
by Quantity One 1D analysis software (Bio-Rad, UK) using a GS-800 Calibrated 
Densitometer (Bio-Rad, UK). 
 
Data and statistical analysis 
The following data and statistical analysis comply with published recommendations on 
experimental design and analysis in pharmacology (Curtis et al., 2015). Group sizes were 
selected on the basis of expected control incidence of VF and the feasibility of detecting an 
effect at p < 0.05, using a published design strategy that allows for data sub analysis to ensure 
that group sizes are not extended to the chosen maximum (n=20/group) if there is no scope 
for an effect approaching statistical significance (Andrag & Curtis, 2013). Gaussian 
distributed variables were subjected to t-tests (where appropriate – 2 groups, 1 time point), or 
ANOVA (1 way or 2 way with repeated measures where applicable), followed by Dunnett’s, 
Tukey’s or Sidak’s post hoc tests (as appropriate) if F was significant, using GraphPad Prism 
6 software. Such values were expressed as mean ± SEM. Western blot densitometry values 
were normalised to the ‘sum of the replicates’ (Degasperi et al., 2014) to minimise the effect 
of sources of variation, before being subjected to statistical analysis. Binomially distributed 
variables (arrhythmia incidence, classified as ‘did’ or ‘did not’ occur) were compared using 
Fisher’s exact test. P < 0.05 was defined as statistically significant.  
 
Drugs and materials 
(-)-Adrenaline, (RS)-atenolol, dobutamine hydrochloride, prazosin hydrochloride, salbutamol 
and terazosin were obtained from Abcam Biochemicals®, UK; butoxamine hydrochloride, (-
)-noradrenaline, patent blue VF sodium salt and (+)-sodium L-ascorbate were obtained from 
Sigma-Aldrich, UK; trimazosin was a gift from Pfizer, UK (compound transfer program). All 
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western blotting solutions and chemicals, and Krebs perfusate salts were obtained from 
Fisher Scientific, Sigma-Aldrich, UK, and VWR International, UK. Solutions and buffers 
were made up in distilled water supplied by a PURELAB flex dispenser and PURELAB 
Option-Q (ELGA LabWater, UK), with a resistivity of 18.2 MΩ. 
Primary antibodies used for western blotting were obtained from the following suppliers: 
rabbit polyclonal anti-cTnI (4002) and rabbit polyclonal anti-p-cTnI Ser23/24 (4004) from 
Cell Signaling Technology; rabbit polyclonal anti-calsequestrin 2 (Casq2; PA1-913) and 
mouse monoclonal anti-RyR2 (MA3-925) from Thermo Fisher Scientific; rabbit polyclonal 
anti-p-RyR2 Ser2808 (A010-30) from Badrilla, and mouse monoclonal anti-α-actinin 
(A7732) from Sigma-Aldrich. The secondary antibodies used for western blotting were 
obtained from the following suppliers: goat polyclonal anti-rabbit (7074) from Cell Signaling 
Technology, and goat polyclonal anti-mouse (P0447) from Dako. 
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Results 
Catecholamines facilitated ischaemia-induced VF when IZ was small 
Varying the location of the coronary ligature obtained the desired IZ sizes, and these were not 
affected by CATs (figure 3A).  
Ventricular arrhythmias 
CATs increased ischaemia-induced VF incidence but only in hearts with small IZs, in which 
control VF incidence was low (figure 3F). Other arrhythmias, more prevalent even with small 
IZs, were not facilitated (figure 3B-E). During reperfusion, the pattern of facilitation was the 
same with CATs increasing VF incidence in hearts with small IZs from 12 to 56%. 
 
Haemodynamic and ECG changes 
CATs increased HR (figure 4A-B) and caused PR shortening (figure 4C), as shown 
previously in perfused rat and mouse hearts (Clements-Jewery et al., 2002; Stables & Curtis, 
2009). Coronary ligation had no effect on HR (figure 4A) but did lower coronary flow, the 
extent of which was dependent on IZ size as expected (Curtis, 1998) (figure 4B). Reperfusion 
had no effect on HR (figure 4A), but caused reactive hyperaemia in all groups 1 minute after 
the start of reperfusion (31 minutes; figure 4B). 
Coronary ligation transiently shortened QT interval in vehicle controls during the first minute 
of ischaemia, an effect that had resolved by 5 minutes of ischaemia and was prevented by 
perfusion with CATs (figure 4D). 
 
Pacing to mimic effects of catecholamines on HR did not facilitate VF 
Pacing at 405 beats min
-1
 maintained HR throughout the experimental protocol (e.g., vs. 259 
± 10 beats min
-1
 in non-paced hearts 10 min after the onset of ischaemia, P<0.05). However, 
pacing did not increase the incidence of any type of ischaemia-induced arrhythmia (figure 
5A-D). IZ sizes were similar between non-paced (10.5 ± 0.9% TVW) and paced hearts (10.3 
± 0.8% TVW) as intended and expected. 
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Identification of AR antagonist concentrations lacking off target pharmacology 
In hearts with large IZs and no added CATs, the α1 AR antagonists, prazosin and terazosin, 
significantly reduced ischaemia-induced VF incidence: prazosin from 67% (vehicle) to 17% 
(1 µM) and 8% (10 µM), and terazosin from 58% (vehicle) to 8% (10 µM). Additionally, 
prazosin and terazosin reduced HR and coronary flow, and prazosin also affected ECG 
intervals (figure 6). All these effects are indicative of AR-independent off target actions 
(Clements-Jewery et al., 2002; Grimm & Flack, 2011; Thandroyen et al., 1983), the nature of 
which are not relevant to the present study, but which rendered these drugs unsuitable as 
selective probes for the α1 AR. 
Further perfusions with an alternative α1 AR antagonist, trimazosin, were therefore 
undertaken. In hearts with large IZs and no added CATs, at 1 µM, neither trimazosin nor the 
AR antagonists atenolol (β1) or butoxamine (β2), affected ischaemia-induced VF (trimazosin: 
67% vs. 67% with vehicle; atenolol: 42% vs. 50% with vehicle; butoxamine: 33% vs. 56% 
with vehicle). In addition, none of these antagonists had any significant effects on ECG 
intervals (appendices figures 1, 2 and 3 A-D). At 10 µM, however, butoxamine and 
trimazosin reduced VF incidence to 0% and 25%, respectively. Thus, the off target NOELs 
for atenolol, butoxamine and trimazosin were 1 µM for each drug.  
 
Identification of AR antagonist concentrations with specificity for the intended AR 
At 1 µM neither butoxamine nor atenolol had any significant effect on the dobutamine CRC 
(–log EC50 or maximum response; figure 7A-B). Butoxamine shifted the salbutamol CRC to 
the right in a concentration-dependent manner, with the change in –log EC50 reaching 
significance at 10 µM (figure 7C-D). Atenolol had no significant effect on the salbutamol 
CRC (figure 7C) or –log EC50 (figure 7D). Neither butoxamine nor atenolol affected the 
maximum relaxation response to salbutamol (figure 7D). Trimazosin caused a concentration-
dependent shift to the right of the PE CRC (figure 7E), and a significant change in the –log 
EC50 (figure 7F) without affecting the PE maximum response (figure 7F). 
Thus, at 1 µM, a lack of off-target AR-mediated effects was confirmed for all 3 drugs, and 
the required on-target AR specificity was confirmed for butoxamine and trimazosin. As a 
result, butoxamine and trimazosin, each at 1 µM, were subsequently used in the 
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‘catecholamine + antagonist’ study in order to identify the AR(s) mediating the facilitation of 
ischaemia-induced VF by CATs in hearts with small IZs. The same concentration of atenolol 
was also taken forward. 
 
Identification of AR(s) mediating facilitation of ischaemia-induced VF by CATs 
The initial finding, that CATs increased ischaemia-induced VF incidence in hearts with small 
IZs, was reproduced in separate hearts (figure 8F). Co-perfusion of CATs with either 1 µM 
atenolol (β1 selective) or butoxamine (β2 selective) inhibited this facilitation, whereas 1 µM 
trimazosin (α1 selective) had no effect (figure 8F). This indicates that when CATs facilitate 
ischaemia-induced VF this required both β1 and β2 agonism. VT facilitation was also 
significantly reduced by 1 µM butoxamine, whilst 1 µM atenolol reduced VT facilitation as a 
non-significant trend (figure 8E). The incidences of less severe arrhythmias were unaffected 
(figure 8B-D). IZ size did not vary between perfusion groups (figure 8A), the means of which 
were between 20-30% TVW as intended. Likewise, TVW was similar in each group (vehicle: 
0.92 ± 0.01 g, CATs: 0.95 ± 0.02 g, CATs + atenolol: 0.89 ± 0.02 g, CATs + butoxamine: 
0.95 ± 0.02 g, CATs + trimazosin: 0.93 ± 0.02 g). 
Haemodynamic and ECG changes 
Atenolol (1 µM) reduced the CAT-induced increase in HR; butoxamine (1 µM) had a weaker 
effect and trimazosin (1 µM) had no effect (figure 9A). CAT-induced increases in coronary 
flow followed a similar pattern (figure 9B). Coronary ligation significantly reduced coronary 
flow in all groups (figure 9B). None of the antagonists prevented the sustained PR shortening 
or QT prolongation caused by CATs (figure 9C-D). The effects of CATs on haemodynamics 
and ECG intervals (figure 9A-D) reproduced initial findings (figure 9A-D).  
 
Independent verification of β AR-specific agonism and β AR-selective antagonism 
Protein phosphorylation in the UZ 
CATs increased cTnI phosphorylation at Ser23/24, a downstream target of β1 AR signalling 
(Puhl et al., 2016), in the UZ. This was prevented by 1 µM atenolol but unaffected by 1 µM 
butoxamine or 1 µM trimazosin (figure 10A-B).  
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Western blots of the RyR2 revealed two bands (figure 10D and figure 10H), corresponding to 
full length RyR2 (565 kDa) and the c-terminal fragment (~400 kDa) (Li et al., 2013). The full 
length RyR2 protein was analysed. Phosphorylation of the RyR2 at Ser2808, a downstream 
target of β2 AR-mediated Gαi signalling that inhibits β1 AR-mediated RyR2 phosphorylation 
(Schmid et al., 2015), was increased in the UZ by 1 µM butoxamine (figure 10C-D). 
Protein phosphorylation in the IZ 
In contrast to UZ data, β1 AR signalling was evident in the IZs of vehicle controls, but 
although CATs tended to increase this, and atenolol blocked the increase, these trends did not 
reach significance (figure 10E-F). Again, in contrast to UZ data, β2 AR signalling in the IZ 
appeared to be unaltered by butoxamine (figure 10G-H).  
 
Test for IZ-mediated facilitation of ischaemia-induced VF using a low flow global 
ischaemia model  
The method successfully achieved complete separation and regulation of flow values between 
low flow groups (‘severe’: 0.8 ml min
-1
, ‘moderate’: 2 ml min
-1
, ‘mild’: 4 ml min
-1
), as was 
intended (figure 11C). Low flow global ischaemia caused sinus bradycardia, and this effect 
was not surmounted by CATs (figure 11D), although in a concurrent set of hearts with 
regional ischaemia (large IZs) CATs increased coronary flow and evoked sinus tachycardia 
(figure 11C-D), as expected. Heart mean temperature fell during ischaemia by no more than 
1˚C (figure 11B). 
Low flow global ischaemia evoked arrhythmias (figure 11E). CATs weakly facilitated 
ischaemia-induced arrhythmias, but only when flow reduction was ‘moderate’, and 
importantly only late after ischaemia onset (≥50 minutes) and not during the phase 1 period 
characteristic of regionally ischaemic hearts; moreover the effect obtained statistical 
significance only for arrhythmia score (figure 11F). QT interval was prolonged by 
catecholamines, but only in the ‘moderate’ flow reduction group (figure 11F-G). 
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Discussion 
Overview 
Published studies do not provide a clear description of the relationship between CATs, 
derived from the circulation or released by cardiac sympathetic innervation, and ischaemia-
related arrhythmogenesis, with some findings indicative of a link (Meredith et al., 1991; 
Slavikova et al., 2007) and others indicative of no link (Botting et al., 1983; Curtis et al., 
1985; Daugherty et al., 1986; Paletta et al., 1989). The rat Langendorff preparation is devoid 
of autonomic nervous reflex or circulating CATs, yet ischaemia- or reperfusion-induced VF 
normally occurs in almost every heart when the IZ is large, meaning that CATs are not 
necessary mediators of ischaemia-induced VF (Ridley et al., 1992; Wilder et al., 2016). The 
aims of this study were therefore (i) to examine the hypothesis that CATs facilitate (rather 
than mediate) ventricular arrhythmias caused by acute myocardial ischaemia, and (ii) to 
identify the ARs involved. When IZ was made small, ischaemia-induced VF was found to be 
facilitated by a mixture of CATs that mimics the cardiac effects of sympathetic tone by 
restoring HR to levels seen in rats in vivo (Curtis et al., 1985) and reducing PR interval, as 
found previously (Clements-Jewery et al., 2002). VF facilitation was not detectable with 
larger IZs. Facilitation was inhibited by atenolol (β1) and butoxamine (β2), but not trimazosin 
(α1), with haemodynamic, western blot and ancillary vascular bioassay data confirming 
antagonist specificity and selectivity at the concentrations used. The findings show that, when 
there is scope, exogenous CATs can increase the risk of ischaemia-induced VF. Scope 
requires the intrinsic risk of VF to be low relative to that occurring with, for example, a large 
IZ of 40% or more of ventricular mass. These data, and the findings from hearts subjected to 
low flow global ischaemia (no VF facilitation during the ‘phase 1’ period of early ischaemia), 
indicate an action mediated primarily if not exclusively in the UZ. The antagonist data 
revealed the effects to be to β1 and β2 AR-mediated, confirmed by western blotting, with 
activation of both receptors necessary for facilitation.  
 
Role of alterations in HR, coronary flow and QT in mediating the facilitation of VF 
In rat isolated hearts with large IZs (~40% TVW) there is a relationship between HR and 
ischaemia-induced VF, but this becomes evident only at HRs in the sinus tachycardia range 
(e.g. 480 beats min
-1
) (Bernier et al., 1989). In dogs in vivo, likewise, variation in HR over the 
normal range for the species (i.e. 150-200 beats min
-1
) had little effect on ischaemia-induced 
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VF risk (Bolli et al., 1986). In the present study, in hearts paced to match the HR of CAT-
perfused hearts (405 beats min
-1
), there was no increase in ischaemia-induced VF incidence, 
meaning that VF facilitation by CATs was not secondary to sinus tachycardia. 
CAT perfusion increased QT interval in the catecholamines + antagonist study (figure 8D), as 
found previously (Clements-Jewery et al., 2002; Clements-Jewery et al., 2006). In previous 
studies, CATs were introduced 90 minutes after the onset of regional ischaemia to hearts that 
had, by this time, recovered sinus rhythm following the paroxysms of early (phase 1) 
arrhythmias (Clements-Jewery et al., 2002). At this time, rat hearts are susceptible to 
developing phase 2 arrhythmias, which manifest primarily by non-re-entrant mechanisms 
(Clements-Jewery et al., 2009), different from the flow of injury current and re-entry that 
operate during the first 30 minutes of ischaemia (phase 1) (Sidorov et al., 2011). CAT 
perfusion failed to facilitate phase 2 arrhythmias (Clements-Jewery et al., 2002; Clements-
Jewery et al., 2006), despite the fact that the (predominantly non-re-entrant) mechanisms of 
phase 2 are supposedly highly susceptible to facilitation by CATs (Antzelevitch & 
Burashnikov, 2011). If the QT prolongation observed in the present study were to have had 
any effect on the re-entrant mechanisms occurring during phase 1, suppression of VF rather 
than facilitation would be the expected outcome (Nattel, 2008). Thus, it is not tenable that the 
observed QT prolongation contributed to the facilitation of ischaemia-induced VF by CATs. 
It should be noted that the lack of identifiable QT interval prolongation by CATs in the varied 
IZ size study (figure 3D) was likely due to differences in baseline (pre-ischaemia/pre-switch) 
QT interval compared to baseline QT interval in the catecholamines + antagonist study 
(figure 8D), meaning that there was reduced scope for detection of CAT-induced 
prolongation. In both studies, QT interval was approximately 80 ms after switching to CATs. 
 
Evidence of drug selectivity and specificity for AR identification 
In order to identify the ARs mediating the CAT effects, it was necessary to select 
concentrations of AR antagonists that exhibited selectivity and specificity. Specificity was 
established from rat aorta myography experiments and/or from evidence of antagonism of 
haemodynamic and intracellular signalling effects of CATs in perfused hearts. Selectivity 
was established from a lack of actions indicative of non-selectivity, in particular, a lack of 
effect on ischaemia-induced VF in hearts perfused without added CATs. 
Page 26 of 60
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
21 
 
Prazosin and terazosin both failed to meet specificity/selectivity requirements. The 
mechanism of their ‘off target’ effects is irrelevant in the present context, albeit prazosin 
certainly possesses Na
+
 channel blocking activity (Daugherty et al., 1986; Thandroyen et al., 
1983). In contrast, atenolol, butoxamine and trimazosin met the selectivity requirements at 1 
µM. This does not necessarily mean that these antagonists do not have any AR-independent 
actions at 1 µM, but it shows that any such actions do not affect any of the haemodynamic 
and ECG variables measured, or inhibit ischaemia-induced arrhythmias in the absence of 
exogenous CATs. Furthermore, 1 µM of these drugs also possessed the required AR 
specificity, judged from ancillary whole heart pharmacology (e.g., effects on HR), ancillary 
rat aorta myography experiments, and/or western blotting. The myography showed that 1 µM 
butoxamine and 1 µM trimazosin had the necessary specificity for β2 or α1 ARs.  The 
specificity of atenolol for the β1 AR, however, could not be established from the aorta assay. 
This was unanticipated, but we found, after completing studies that the rat thoracic aortae has 
a low expression of β1 ARs (Perez-Aso et al., 2014). Specificity of atenolol for the β1 AR was 
nevertheless established independently from its ability to antagonise the increase in HR 
caused by CATs (figure 9A) and from the abolition of the CAT-stimulated β1 AR signal (p-
cTnI/cTnI; figure 10A). The array of effects on multiple variables therefore confirmed the 
specificity and selectivity of 1µM of butoxamine, trimazosin and atenolol, establishing their 
validity as pharmacological tools in the present context. 
 
Facilitation of ischaemia-induced VF via actions in the IZ 
Collateral flow in the rat IZ is <5% normal flow (Maxwell et al., 1987) and the ischaemic 
milieu in the rat heart is effectively stagnant and not conducive to delivery and accumulation 
of labile substances such as CATs. However should sufficient amounts of CATs be able to 
access the IZ during early ischaemia, as may occur in well-collateralised hearts of some 
species other than rat, AR activation in the IZ may be sufficient to facilitate ischaemia-
induced arrhythmias. To test this, a low flow global ischaemia model was used, in which the 
site of action of perfused CATs is, unavoidably and exclusively, the IZ, and residual flow can 
be controlled precisely. CATs did facilitate ischaemia-induced arrhythmias in these hearts, 
but effects were weak, detectable only by using an arrhythmia score that (unlike VF 
incidence) permits use of powerful parametric statistics, and required a prolonged period of 
ischaemia to become apparent (well beyond the window of phase 1 arrhythmias associated 
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with regional ischaemia) (Curtis, 1998). Furthermore facilitation occurred only when 
coronary flow was reduced ‘moderately’ to 2 ml min
-1
, and not when flow reduction was mild 
or severe, consistent with a need for residual flow to be sufficiently high to deliver CATs 
swiftly enough to preclude the perfused tissue degrading them, yet sufficiently low to cause 
ischaemia of necessary severity to generate an arrhythmogenic substrate. Overall, the weak 
facilitation of ischaemia-induced VF by CATs acting within the IZ was insufficient, and far 
too delayed, to have contributed meaningfully to the facilitation of VF observed during 
regional ischaemia.  
There is evidence that endogenous NA may accumulate in the ischaemic region owing to 
local acidity driving uptake 1 in the reverse mode in the surviving sympathetic afferents, and 
that this occurs even in rat isolated hearts in which the postganglionic sympathetic afferents 
are unavoidably detached from the CNS (Schömig et al., 1984). However this process is 
unlikely to have contributed to any of the present study outcomes. There are several reasons 
for this. 
The first is that the key variable we examined was the increase in VF incidence caused by 
perfusion with catecholamines delivered to the uninvolved non-ischaemic region. It is 
difficult to conceptualise how uptake 1 in the reverse mode in the ischaemic region could be 
increased by perfusing the uninvolved region with catecholamines, or how this, if it occurs, 
would account for the increase in ischaemia-induced VF caused by perfusion with 
catecholamines. To examine the receptor mechanism we used AR antagonists shown to have 
no action on ischaemia-induced VF in hearts perfused without added catecholamines 
(meaning these drugs had no effect on the actions of any endogenous NA released via uptake 
1 in the reverse mode during ischaemia). Likewise, it is not possible to explain inhibition of 
the increase in ischaemia-induced VF caused by perfusion with catecholamines by the two β 
AR antagonists (butoxamine and atenolol at 1 µM) on the basis of a supposed inhibition of 
the actions of endogenous NA in the ischaemic region (released by uptake 1 in the reverse 
mode) because these drugs at the concentration used (1 µM) had no effect on ischaemia-
induced VF incidence in hearts perfused without added catecholamines. 
Whether or not NA released by uptake 1 in the reverse mode can contribute to ischaemia-
induced VF in a wider sense is a separate issue that may warrant separate investigation. In 
view of possible reader interest in the topic, we have expanded on the role of uptake 1 in 
ischaemia-induced VF below. 
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Interestingly, the data derived by Schömig et al. (1984) do not show that uptake 1 in the 
reverse mode operates during ischaemia. Schömig et al. (1984) measured NA release during 
reperfusion. Other investigators have made similar measurements, again during reperfusion 
(Wilde et al., 1988). One of the few papers that measured NA within ischaemic tissue itself 
found a reduction in tissue NA content in a rat in vivo model after 20 and 30 minutes of 
ischaemia (earlier time points not examined) (Abrahamsson et al., 1981). The latter study 
refers to the conflicting evidence for changes in tissue NA during ischaemia. There is 
evidence that NA accumulates in the interstitial fluid in the ischaemic myocardium from 
work by Lameris et al. (2000) using microdialysis probes implanted into the left ventricle of 
pigs. But just as in the case of Schomig’s rat heart data (Schömig et al., 1984), the time 
course of accumulation shows a large with the known temporal pattern of VF during 
ischaemia; interstitial NA was still rising 60 minutes after the onset of ischaemia, long after 
the phase 1 arrhythmia period is over in pigs, while values at the peak of arrhythmia 
incidence were relatively low (Lameris et al., 2000). 
Species differences, or experimental setting, may also be an issue. The study by Lameris et 
al. (2000) shows that ischaemia causes release of NA in pigs in vivo. However, as noted 
above, the evidence for this in isolated denervated rat hearts is less persuasive. Indeed, 
Daugherty et al. (1986) found that during continuous regional ischaemia in the rat 
Langendorff preparation (with no added catecholamines), the low level of collateral flow 
allowed the release of accumulating lactate to be detected during ischaemia, but there was no 
commensurate release of NA. This confirms that the release of NA during reperfusion 
observed by Schömig et al. (1984) in the rat Langendorff was, in part at least, reperfusion-
induced, rather than washout of NA that had accumulated during ischaemia. 
There is actually very little work that addresses specifically the role of uptake 1 in the reverse 
mode as an arrhythmogenic mechanism. Few of the published studies measure arrhythmias 
and NA contiguously. In one of the more recent relevant articles published on the subject, 
(Du et al., 1998), the authors noted “We found that depletion of noradrenaline prevented 
arrhythmias in anoxic hearts but failed to do so in ischemic hearts” and added that “in 
noradrenaline-depleted hearts, desipramine and imipramine . . . remained potent in preventing 
arrhythmias”. Ischaemia-induced VF can therefore still occur in hearts depleted of 
catecholamines, and this is inhibited by drugs that inhibit uptake 1, meaning there can be no 
obligatory or necessary role for uptake 1 in the reverse mode in the mediation of ischaemia-
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induced VF, and that the drug tools used earlier by Schömig et al. (1984), and others (Kurz et 
al., 1995; Richardt et al., 2006) evidently lack selectivity for uptake 1. 
Overall, these data show there is no basis for giving serious consideration to the possibility 
that uptake 1 in the reverse mode has relevance to the present study’s findings. 
 
Identification of the ARs mediating facilitation of VF 
Given the selectivity and specificity of 1 µM atenolol and butoxamine, their effects on VF 
indicates, somewhat unexpectedly, that simultaneous activation of β1 and β2 ARs is necessary 
for VF facilitation by CATs since, if activation of only one or other AR were necessary, only 
one or other of the antagonists would have had the capability to reduce VF incidence. 
With respect to mechanism, separate pacing studies showed that VF facilitation was not a 
secondary consequence of an increase in HR, and inhibition of VF facilitation was not 
secondary to any inhibition of the increase in HR.  
In UZs, atenolol prevented the phosphorylation of cTnI by CATs, indicative of inhibition of 
β1 AR signalling (Puhl et al., 2016), whereas butoxamine and trimazosin had no effect. These 
data confirmed the evidence outlined above that atenolol inhibited VF facilitation via β1 
antagonism whereas butoxamine inhibited VF facilitation via a β1-independent action.  
Evidence of suppression of β2 AR mediated signalling by butoxamine was sought by probing 
for RyR2 phosphorylation, a relatively novel and unestablished method that depends upon β1 
AR signalling increasing RyR2 phosphorylation (via Gαs), whilst β2 AR signalling attenuates 
it (via Gαi) (Schmid et al., 2015). The, p-RyR2 levels in the UZ were increased by CATs + 
butoxamine vs. vehicle-perfused hearts, as anticipated. However, p-RyR2 levels were 
unchanged in the CATs + atenolol group, which would suggest that the RyR2 is 
phosphorylated additionally by AR-independent mechanisms. This would also explain the 
detectable baseline levels of p-RyR2 in the UZs of vehicle-perfused hearts, and lack of 
detectable attenuation of p-RyR2 in CAT + atenolol-perfused hearts in the present study. The 
β2 AR signalling assessment was therefore disappointing. Nevertheless, the key finding was 
that butoxamine (but not atenolol) demonstrated specificity at the β2 AR. Taken together, the 
present data confirm that butoxamine reduced the facilitation of ischaemia-induced VF by 
CATs via selective and specific β2 AR antagonism. 
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Although we processed IZ tissue, the data were shown for purposes of transparency rather 
than to explore any hypothesis. The IZ western blots were more variable than blots from the 
UZs, as one might expect given that ischaemia as well as CATs can affect AR signal 
expression levels. For example, cTnI phosphorylation at Ser23/24 is elevated during regional 
ischaemia in murine hearts (Nixon et al., 2014), and the acidic conditions of ischaemia can 
increase p-cTnI in rat hearts (Mundina-Weilenmann et al., 1996).  
Nevertheless, atenolol and butoxamine had no effect on β1 or β2 signalling in the IZ, 
consistent with the more compelling evidence discussed above that the facilitation of VF by 
CATs and its inhibition by atenolol or butoxamine were mediated primarily if not exclusively 
in the UZ.  
 
Mechanistic insight and limitations of present findings 
It was not our objective to explore the electrophysiological mechanisms by which CATs 
facilitate ischaemia-induced VF. This is partly because it is well known that ischaemia-
induced changes in IZ AP shape and conduction velocity that generate AP heterogeneity 
between the IZ and UZ, and facilitate arrhythmogenic flow of injury current (Janse et al., 
1980; Janse & Wit, 1989) are exacerbated by CATs via actions in the UZ (the AP depolarises 
faster, increasing conduction velocity, and hyperpolarises to a more negative membrane 
potential during diastole) (Dorian, 2005; Janse & Wit, 1989). What was not known, and what 
formed the focus of this study, was the extent to which these effects of CATs contributes to 
ischaemia-induced VF. The mechanistic insight provided by the present data concerns the 
identification of the scope for VF facilitation by CATs (i.e., the potential relevance), the site 
of action and the identity of the receptor mechanisms responsible (which are targetable by 
drugs).  
As in previous studies (Clements-Jewery et al., 2002; Clements-Jewery et al., 2006), our 
method of mimicking sympathetic influence in a preparation that ordinarily has none is a 
practicable and tractable approach, and one that is validated in terms of achievement of what 
is intended – restoration of cardiac variables to levels typical of the conscious rat (Clements-
Jewery et al., 2002). However, perfusion with any mix of NA and AD cannot mimic precisely 
the influence of the sympathetic nervous system on the heart in vivo, which comprises a mix 
of circulating CATs and noradrenergic neurotransmission, neither of which are ever in true 
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steady state, meaning the possibility of additional VF-facilitating actions secondary to 
autonomic turbulence. Modelling this may be warranted in future studies. 
 
Conclusion 
In rat isolated perfused hearts in which baseline risk of phase 1 ischaemia-induced VF was 
made deliberately low, exogenous CATs facilitated VF with effects mediated predominantly 
in the UZ. The facilitation occurred via β1 and β2 agonism, with activation of both types of 
AR necessary. These findings may partially explain why, in humans, β blockers (of varying 
selectivity) have only moderate benefit in reducing mortality and ventricular arrhythmias in 
patients at risk of acute MI (β-Blocker Heart Attack Study Group, 1981), since VF risk is 
likely to be reduced only in patients with smaller IZs. 
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Tables 
Table 1: Intended IZ size 
Position of Ligature IZ size % TVW 
Distal Small <20 
Medial Medium 25-35 
Proximal Large >42 
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Figure Legends 
Figure 1: The 5 types of ventricular arrhythmias occurring during ischaemia and reperfusion in Langendorff-
perfused rat hearts, as defined by the Lambeth Conventions II (Curtis et al., 2013). VPB: ventricular premature 
beat, BG: bigeminy, VT: ventricular tachycardia, VF: ventricular fibrillation. 
 
Figure 2: Experimental protocols for varied IZ size study, pacing study, antagonist only studies, catecholamines 
+ antagonist study and low flow global ischaemia study. IZ: ischaemic zone, CATs: catecholamine mixture 
(313 nM noradrenaline + 75 nM adrenaline). 
 
Figure 3: IZ sizes resulting from distal, medial or proximal ligation of the left coronary artery (A) and incidence 
(% of group) of increasingly severe ventricular arrhythmias (VPB to VF) during 30 minutes of regional 
ischaemia (B-F) in hearts with small, medium and large IZs (varied IZ size study). n = 20 per group; mean ± 
SEM (A) or incidence (B-F); * p < 0.05. TVW: total ventricular weight, IZ: ischaemic zone, VPB: ventricular 
premature beat, BG: bigeminy, VT: ventricular tachycardia, VF: ventricular fibrillation, CATs: catecholamine 
mixture (313 nM noradrenaline + 75 nM adrenaline). 
 
Figure 4: Haemodynamic and ECG changes in hearts with small, medium and large IZs (varied IZ size study). 
A) HR, B) coronary flow, C) PR and D) QT intervals. n = 20 per group; mean ± SEM; * p < 0.05 all CATs 
groups vs. time-matched corresponding control groups; † p < 0.05 small IZ control vs. time-matched small IZ + 
CATs; # p < 0.05 medium IZ control vs. time-matched medium IZ + CATs; § p < 0.05 large IZ control vs. time-
matched large IZ + CATs. HR: heart rate, PR: PR interval, QT: QT90 interval, CATs: catecholamine mixture 
(313 nM noradrenaline + 75 nM adrenaline). 
 
Figure 5: Incidence (% of group) of increasingly severe ventricular arrhythmias (VPB to VT) during 30 minutes 
of regional ischaemia and 1 minute of reperfusion in hearts with small IZs, with or without left atrial pacing 
(pacing study). n = 12 per group (ischaemia) or 6 per group (reperfusion). N.B. the incidence of ischaemia- and 
reperfusion-induced VF was zero in both groups. VPB: ventricular premature beat, BG: bigeminy, VT: 
ventricular tachycardia. 
 
Figure 6: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM prazosin (A-D), 
and 1 or 10 µM terazosin (E-H). HR (A+E), coronary flow (B+F), PR (C+G) and QT intervals (D+H). n = 12 
per group; mean ± SEM; * p < 0.05 vs. time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 
interval. 
 
Figure 7: Dobutamine (A), salbutamol (C) and PE (E) CRCs in the presence of vehicle, 1 or 10 µM atenolol, 
butoxamine or trimazosin, and –log EC50s and maximum response values (B, D, F) derived from the CRCs. n = 
5 per group; mean ± SEMs; * p < 0.05. CRCs: concentration response curves, PE: phenylephrine. 
 
Figure 8: IZ size (A) and incidence of increasingly severe ventricular arrhythmias (VPB to VF; B-D) during 30 
minutes of regional ischaemia in hearts with small IZs, perfused with vehicle, CATs or CATs + 1 µM atenolol, 
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butoxamine or trimazosin. n = 20 per group; mean ± SEM (A) or incidence (B-F); * p < 0.05. TVW: total 
ventricular weight, IZ: ischaemic zone, VPB: ventricular premature beat, BG: bigeminy, VT: ventricular 
tachycardia, VF: ventricular fibrillation, CATs: catecholamine mixture (313 nM noradrenaline + 75 nM 
adrenaline). 
 
Figure 9: Haemodynamic and ECG changes in hearts with small IZs perfused with vehicle, CATs or CATs + 1 
µM atenolol, butoxamine or trimazosin. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 20 per group; 
mean ± SEM; p < 0.05 indicated in the figure. HR: heart rate, PR: PR interval, QT: QT90 interval, CATs: 
catecholamine mixture (313 nM noradrenaline + 75 nM adrenaline). 
 
Figure 10: Quantification of UZ (A-D) and IZ (E-H) western blots probed for total cTnI and p-cTnI (A-B, E-
F), and total RyR2 and p-RyR2 (C-D, G-H). n = 5 per group; mean ± SEM; * p < 0.05. p-cTnI: 
phosphorylated cardiac troponin I, Casq2: calsequestrin 2 (cardiac), p-RyR2: phosphorylated ryanodine 
receptor type 2 (cardiac), CATs: catecholamine mixture (313 nM noradrenaline + 75 nM adrenaline). 
 
Figure 11: IZ size in hearts with large IZs (A), heart temperature (B), coronary flow (C), HR (D), mean 5 point 
arrhythmia score in hearts perfused without CATs (E), 5 point arrhythmia score from hearts with ‘moderate’ (2 
ml min
-1
) low flow global ischaemia (F), and QT interval at 60 minutes of ischaemia (G) in hearts with low flow 
global ischaemia or large IZs, perfused with vehicle or CATs. n = 12 per group; mean ± SEM; † p < 0.05 vs. 
time-matched large IZ vehicle control; * p < 0.05. HR: heart rate, QT: QT90 interval, CATs: catecholamine 
mixture (313 nM noradrenaline + 75 nM adrenaline). 
 
Appendices Figure 1: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
atenolol. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM; * p < 0.05 vs. 
time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 interval. 
 
Appendices Figure 2: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
butoxamine. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM; * p < 0.05 
vs. time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 interval. 
 
Appendices Figure 3: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
trimazosin. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM. HR: heart 
rate, PR: PR interval, QT: QT90 interval. 
 
Appendices Figure 4: Relationship between TVW and VF incidence from all hearts used in all studies. TVW: 
total ventricular weight, VF: ventricular fibrillation. Mean ± SEM, Pearson correlation calculation. 
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Figure 1: The 5 types of ventricular arrhythmias occurring during ischaemia and reperfusion in Langendorff-
perfused rat hearts, as defined by the Lambeth Conventions II (Curtis et al., 2013). VPB: ventricular premature 
beat, BG: bigeminy, VT: ventricular tachycardia, VF: ventricular fibrillation. 
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Figure 2: Experimental protocols for varied IZ size study, pacing study, antagonist only studies, catecholamines 
+ antagonist study and low flow global ischaemia study. IZ: ischaemic zone, CATs: catecholamine mixture (313 
nM noradrenaline + 75 nM adrenaline). 
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Figure 3: IZ sizes resulting from distal, medial or proximal ligation of the left coronary artery (A) and incidence 
(% of group) of increasingly severe ventricular arrhythmias (VPB to VF) during 30 minutes of regional 
ischaemia (B-F) in hearts with small, medium and large IZs (varied IZ size study). n = 20 per group; mean ± 
SEM (A) or incidence (B-F); * p < 0.05. TVW: total ventricular weight, IZ: ischaemic zone, VPB: ventricular 
premature beat, BG: bigeminy, VT: ventricular tachycardia, VF: ventricular fibrillation, CATs: catecholamine 
mixture (313 nM noradrenaline + 75 nM adrenaline). 
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Figure 4: Haemodynamic and ECG changes in hearts with small, medium and large IZs (varied IZ size study). 
A) HR, B) coronary flow, C) PR and D) QT intervals. n = 20 per group; mean ± SEM; * p < 0.05 all CATs 
groups vs. time-matched corresponding control groups; † p < 0.05 small IZ control vs. time-matched small IZ + 
CATs; # p < 0.05 medium IZ control vs. time-matched medium IZ + CATs; § p < 0.05 large IZ control vs. time-
matched large IZ + CATs. HR: heart rate, PR: PR interval, QT: QT90 interval, CATs: catecholamine mixture 
(313 nM noradrenaline + 75 nM adrenaline). 
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Figure 5: Incidence (% of group) of increasingly severe ventricular arrhythmias (VPB to VT) during 30 minutes 
of regional ischaemia and 1 minute of reperfusion in hearts with small IZs, with or without left atrial pacing 
(pacing study). n = 12 per group (ischaemia) or 6 per group (reperfusion). N.B. the incidence of ischaemia- and 
reperfusion-induced VF was zero in both groups. VPB: ventricular premature beat, BG: bigeminy, VT: 
ventricular tachycardia. 
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Figure 6: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM prazosin (A-D), 
and 1 or 10 µM terazosin (E-H). HR (A+E), coronary flow (B+F), PR (C+G) and QT intervals (D+H). n = 12 
per group; mean ± SEM; * p < 0.05 vs. time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 
interval.
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Figure 7: Dobutamine (A), salbutamol (C) and PE (E) CRCs in the presence of vehicle, 1 or 10 µM atenolol, 
butoxamine or trimazosin, and –log EC50s and maximum response values (B, D, F) derived from the CRCs. n = 5 
per group; mean ± SEMs; * p < 0.05. CRCs: concentration response curves, PE: phenylephrine. 
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Figure 8: IZ size (A) and incidence of increasingly severe ventricular arrhythmias (VPB to VF; B-D) during 30 
minutes of regional ischaemia in hearts with small IZs, perfused with vehicle, CATs or CATs + 1 µM atenolol, 
butoxamine or trimazosin. n = 20 per group; mean ± SEM (A) or incidence (B-F); * p < 0.05. TVW: total 
ventricular weight, IZ: ischaemic zone, VPB: ventricular premature beat, BG: bigeminy, VT: ventricular 
tachycardia, VF: ventricular fibrillation, CATs: catecholamine mixture (313 nM noradrenaline + 75 nM 
adrenaline). 
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Figure 9: Haemodynamic and ECG changes in hearts with small IZs perfused with vehicle, CATs or CATs + 1 
µM atenolol, butoxamine or trimazosin. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 20 per group; 
mean ± SEM; p < 0.05 indicated in the figure. HR: heart rate, PR: PR interval, QT: QT90 interval, CATs: 
catecholamine mixture (313 nM noradrenaline + 75 nM adrenaline). 
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Figure 10: Quantification of UZ (A-D) and IZ (E-H) western blots probed for total cTnI and p-cTnI (A-B, E-
F), and total RyR2 and p-RyR2 (C-D, G-H). n = 5 per group; mean ± SEM; * p < 0.05. p-cTnI: 
phosphorylated cardiac troponin I, Casq2: calsequestrin 2 (cardiac), p-RyR2: phosphorylated ryanodine 
receptor type 2 (cardiac), CATs: catecholamine mixture (313 nM noradrenaline + 75 nM adrenaline). 
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Figure 11: IZ size in hearts with large IZs (A), heart temperature (B), coronary flow (C), HR (D), mean 5 point 
arrhythmia score in hearts perfused without CATs (E), 5 point arrhythmia score from hearts with ‘moderate’ (2 
ml min-1) low flow global ischaemia (F), and QT interval at 60 minutes of ischaemia (G) in hearts with low flow 
global ischaemia or large IZs, perfused with vehicle or CATs. n = 12 per group; mean ± SEM; † p < 0.05 vs. time-
matched large IZ vehicle control; * p < 0.05. HR: heart rate, QT: QT90 interval, CATs: catecholamine mixture 
(313 nM noradrenaline + 75 nM adrenaline). 
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Appendices Figure 1: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
atenolol. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM; * p < 0.05 vs. 
time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 interval. 
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Appendices Figure 2: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
butoxamine. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM; * p < 0.05 vs. 
time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 interval. 
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Appendices Figure 3: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
trimazosin. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM. HR: heart rate, 
PR: PR interval, QT: QT90 interval. 
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Appendices Figure 4: Relationship between TVW and VF incidence from all hearts used in all studies. TVW: 
total ventricular weight, VF: ventricular fibrillation. Mean ± SEM, Pearson correlation calculation. 
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Atenolol, butoxamine and trimazosin haemodynamics 
The AR antagonists atenolol (β1), butoxamine (β2), and trimazosin (͍α1) at 1 µM had no 
significant effects on ECG intervals or coronary flow vs. vehicle-perfused hearts (appendices 
figure 1, appendices figure 2 and appendices figure 3 A-D). 
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Appendices Figure 1: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
atenolol. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM; * p < 0.05 vs. 
time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 interval. 
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Appendices Figure 2: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
butoxamine. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM; * p < 0.05 
vs. time-matched vehicle. HR: heart rate, PR: PR interval, QT: QT90 interval. 
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Appendices Figure 3: Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 µM 
trimazosin. A) HR, B) coronary flow, C) PR and D) QT intervals. n = 12 per group; mean ± SEM. HR: heart 
rate, PR: PR interval, QT: QT90 interval. 
 
 
Relationship between heart weight and VF incidence across all studies 
All studies were randomised so any relationship between heart weight and VF incidence will 
have had no influence on differences in VF incidence between groups, or account for any 
effects seen. TVW vs. ischaemia-induced VF incidence from hearts from all studies used in 
this paper (30 study data sets) has been plotted (appendices figure 4). 
There is no correlation between TVW and ischaemia-induced VF incidence according to 
Pearson correlation calculation. This shows that TVW is not an independent source of error 
in our studies. Thus, although body weight and heart size varied in the study overall, this was 
not a significant source of variance with respect to ischaemia-induced VF incidence. 
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Appendices Figure 4: Relationship between TVW and VF incidence from all hearts used in all studies. TVW: 
total ventricular weight, VF: ventricular fibrillation. Mean ± SEM, Pearson correlation calculation. 
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Western Blot PDF for review (uncropped blots from Figure 9) 
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